Managing the consequences of obstruction

European Urology, Supplements

Volumn 1, Issue 9, 2002, Pages 21-27

  Tubaro, Andrea ^a   Miano, Lucio ^a  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

Bladder; Bladder wall hypertrophy; BPH; LUTS; Obstruction; Treatment failure; 1 adrenoceptor antagonist

Indexed keywords

ALFUZOSIN; ALPHA 1 ADRENERGIC RECEPTOR BLOCKING AGENT; DOXAZOSIN; FINASTERIDE; INDORAMIN; PRAZOSIN; TAMSULOSIN; TERAZOSIN;

BLADDER INJURY; BLADDER NECK STENOSIS; CLINICAL TRIAL; HUMAN; MUSCLE HYPERTROPHY; NONHUMAN; PERIPHERAL NERVOUS SYSTEM; PRIORITY JOURNAL; PROSTATE HYPERTROPHY; REVIEW; SMOOTH MUSCLE; TREATMENT OUTCOME; URINARY TRACT OBSTRUCTION;

EID: 1642293932     PISSN: 15699056     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1569-9056(02)00120-3     Document Type: Article

References (28)

1. Lepor H., Williford W.O., Barry M.J., Haakenson C., Jones K. The impact of medical therapy on bother due to symptoms, quality of life and global outcome and factors predicting response. J. Urol. 160:1998;1358-1367.
2. Lepor H., Nieder A., Feser J., O'Connel C., Dixon C. Effect of terazosin on prostatism in men with normal and abnormal peak urinary flow rates. Urology. 49:1997;476-480.
3. Arnold E.P. Tamsulosin in men with confirmed bladder outlet obstruction: a clinical and urodynamic analysis from a single centre in New Zealand. BJU Int. 87:2001;24-31.
4. 1D subtype in filling symptoms and effects of ageing on vascular expression. BJU Int. 85(Suppl 2):2000;6-11.
5. 1-adrenoceptor antagonists. Eur. Urol. 40(Suppl 4):2001;5-11.
6. Levin R.M., Levin S.S., Zhao Y., Buttyan R. Cellular and molecular aspects of bladder hypertrophy. Eur. Urol. 32(Suppl 1):1997;15-21.
7. Levin R.M., Haugaard N., O'Connor L., Buttyan R., Das A., Dixon J.S., Gosling J.A. Obstructive response of human bladder to BPH vs. rabbit bladder response to partial outlet obstruction: a direct comparison. Neurourol. Urodyn. 19:2000;609-629.
8. Anderson J.B., Roehrborn C.G., Schalken J.A., Emberton M. The progression of benign prostatic hyperplasia: examining the evidence and determining the risk. Eur. Urol. 39:2001;390-399.
9. Levin R.M., Monson F.C., Haugaard N., Buttyan R., Hudson A., Roelofs M. et al. Genetic and cellular characteristics of bladder outlet obstruction. Urol. Clin. North Am. 22:1995;263-283.
10. Manieri C., Carter S.C., Romano G., Trucchi A., Valenti M., Tubaro A. The diagnosis of bladder outlet obstruction in men by ultrasound measurement of bladder wall thickness. J. Urol. 159:1998;761-765.
11. Kojima M., Inui E., Ochiai A., Naya Y., Ukimura O., Watanabe H. Ultrasonic estimation of bladder weight as a measure of bladder hypertrophy in men with infravesical obstruction: a preliminary report. Urology. 47:1996;942-947.
12. Naya Y., Kojima M., Honjyo H., Ochiai A., Watanabe H. Intraobserver and interobserver variance in the measurement of ultrasound-estimated bladder weight. Ultrasound Med. Biol. 24:1998;771-773.
13. Oelke M., Höfner K., Jonas U. Detrusor wall thickness is an indicator for BOO. Eur. Urol. 39(Suppl 5):2001;67. [Abstract 260].
14. Kojima M., Inui E., Ochiai A., Naya Y., Ukimura O., Watanabe H. Noninvasive quantitative estimation of infravesical obstruction using ultrasonic measurement of bladder weight. J. Urol. 157:1997;476-479.
15. Laniado ME, Ockrim J, Marronaro A, Tubaro A, Roco B, Carter S. Bladder wall thickness and free flow rate in a logistic regression predict patients who do not have lower urinary tract obstruction on pressure/flow urodynamic studies. J Urol 2002;167(Suppl 4) [Abstract 1065].
16. Levin R.M., Chichester P., Hass M.A., Gosling J.A., Buttyan R. Obstructive bladder dysfunction: morphological, biochemical and molecular changes. Eur Urol Suppl. 1(9):2002;14-20.
17. Tubaro A., Carter S., Hind A., Vicentini C., Miano L. A prospective study of the safety and efficacy of suprapubic transvesical prostatectomy in patients with benign prostatic hyperplasia. J. Urol. 166:2001;172-176.
18. Kojima M., Inui E., Ochiai A., Naya Y., Kamoi K., Ukimura O.et al. Reversible change of bladder hypertrophy due to benign prostatic hyperplasia after surgical relief of obstruction. J. Urol. 158:1997;89-93.
19. 1- blocker. Eur. Urol. 37:2000;103. [Abstract 411].
20. Levin R.M., Leggett R.E., Eagen G., Das A.K. Effect of doxazosin on bladder function after partial outlet obstruction in rats. J. Urol. 165(Suppl 5):2001;206. [Abstract 852].
21. Pinggera G.M., Schuster A., Pallwein L., Klauser A., Frauscher F., Furtmüller B.et al. Alpha-blockers increase vesical and prostatic blood flow and bladder capacity. J. Urol. 167(Suppl 4):2002;373. [Abstract 1485].
22. Wasson JH, Reda DJ, Bruskewitz RC, Elinson J, Keller AM, Henderson WG, for the Veterans Affairs Cooperative Study Group on Transurethral Resection of the Prostate. A comparison of transurethral surgery with watchful waiting for moderate symptoms of benign prostatic hyperplasia. N Engl J Med 1995;332:75-79.
23. Barry M.J., Fowler F.J., Bin L., Pitts C.J., Harris C.J., Mulley A.G. The natural history of patients with benign prostatic hyperplasia as diagnosed by North American urologists. J. Urol. 157:1997;10-15.
24. Jacobsen S.J., Girman C.J., Guess H.A., Rhodes T., Oesterling J.E., Lieber M.M. Natural history of prostatism: longitudinal changes in voiding symptoms in community-dwelling men. J. Urol. 155:1996;595-600.
25. Michel M.C., Goepel M. Lower urinary tract symptoms suggestive of benign prostatic obstruction - What's the long-term effectiveness of medical therapies. Eur. Urol. 39(Suppl 3):2001;20-25.
26. Kirby R, Altwein JE, Bartsch G, Boyle P, Jardin A, Roehrborn C, for the PREDICT Investigators. Results of the PREDICT (Prospective European Doxazosin and Combination Therapy). J Urol 1999;161(Suppl):266 [Abstract 1027].
27. McConnell JD, for the MTOPS Steering Committee. The long-term effects of medical therapy on the progression of BPH: Results from the MTOPS trial. J Urol 2002;167(Suppl 4):265 [Abstract 1042].
28. Logie J.W., Clifford G.M., Farmer R.D.T., Meesen B.W.P. Lower urinary tract symptoms suggestive of benign prostatic obstruction - Triumph: The role of general practice databases. Eur. Urol. 39(Suppl 3):2001;42-47.